President-elect Joe Biden plans to protect and strengthen the Affordable Care Act, the public health insurance scheme passed in 2010 by then President Barack Obama. Over the last few years, the Affordable Care Act has been under relentless attack [1], and the US Supreme Court is currently considering a case attempting to strike down the law.
- INICIO
-
Genéricos
Novedades
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Investigación
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
General
- Crecimiento de medicamentos genéricos en Brasil y Venezuela
- EMA launches European shortages monitoring platform to tackle persistent medicine shortages
- Penetración de los medicamentos genéricos en México y Brasil
- FDA releases one-year progress report for the Generic Drug Cluster
-
Biosimilares
Novedades
- EC approves golimumab biosimilar Gotenfia and ranibizumab biosimilar Ranluspec
- EMA recommends approval for teriparatide biosimilar Zandoriah
- FDA approves third interchangeable ranibizumab biosimilar Nufymco
- FDA approves Poherdy (first interchangeable pertuzumab) and Armlupeg (pegfilgrastim) biosimilars
Investigación
- OECD study finds no direct link between advertising rules and biosimilar uptake
- Alcanzar los objetivos ASG en el desarrollo farmacéutico
- What is the future for the US biosimilar interchangeability designation
- Estudios de eficacia clínica en biosimilares: ¿siguen siendo necesarios?
General
- La SBR publica un posicionamiento sobre la intercambiabilidad segura entre biológicos originales y biosimilares
- Biosimilars approved in the US
- Samsung Bioepis wins Pyzchiva case; Regeneron patent rulings threaten foreign biosimilars
- Biosimilars approved in Europe
- MORE EDITORIAL SECTIONS
- Search




Post your comment